Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
暂无分享,去创建一个
G. Mills | G. Hortobagyi | L. Pusztai | K. Do | W. Symmans | V. Valero | J. Murray | F. Meric-Bernstam | S. Giordano | A. González-Angulo | M. Dryden | J. Litton | A. Brewster | N. Ibrahim | A. Akcakanat | J. Moore | S. Liu | S. Moulder-Thompson | S. Palla | E. Tarco | A. Sahin | M. Green | D. Crawford | P. Flores | K. Koenig | H. Chen